Financial burden of men with localized prostate cancer: a process paper

Frontiers in Psychology

Psychology

Hannah E. Rice¹  Su-Hsin Chang¹  Ashley J. Housten¹  Bettina F. Drake¹  Allison J. L'Hotta¹  Mary C. Politi¹  Eric H. Kim²  Robin Wright-Jones³ 

[1] Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States;Division of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States;The Empowerment Network, St. Louis, MO, United States;

关键词: prostate cancer;    financial toxicity;    cost estimates;    multidisciplinary collaboration;    shared decision making (SDM);    quality of life;   

DOI  :  10.3389/fpsyg.2023.1176843

 received in 2023-02-28, accepted in 2023-06-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundMany individuals undergoing cancer treatment experience substantial financial hardship, often referred to as financial toxicity (FT). Those undergoing prostate cancer treatment may experience FT and its impact can exacerbate disparate health outcomes. Localized prostate cancer treatment options include: radiation, surgery, and/or active surveillance. Quality of life tradeoffs and costs differ between treatment options. In this project, our aim was to quantify direct healthcare costs to support patients and clinicians as they discuss prostate cancer treatment options. We provide the transparent steps to estimate healthcare costs associated with treatment for localized prostate cancer among the privately insured population using a large claims dataset.MethodsTo quantify the costs associated with their prostate cancer treatment, we used data from the Truven Health Analytics MarketScan Commercial Claims and Encounters, including MarketScan Medicaid, and peer reviewed literature. Strategies to estimate costs included: (1) identifying the problem, (2) engaging a multidisciplinary team, (3) reviewing the literature and identifying the database, (4) identifying outcomes, (5) defining the cohort, and (6) designing the analytic plan. The costs consist of patient, clinician, and system/facility costs, at 1-year, 3-years, and 5-years following diagnosis.ResultsWe outline our specific strategies to estimate costs, including: defining complex research questions, defining the study population, defining initial prostate cancer treatment, linking facility and provider level related costs, and developing a shared understanding of definitions on our research team.Discussion and next stepsAnalyses are underway. We plan to include these costs in a prostate cancer patient decision aid alongside other clinical tradeoffs.

【 授权许可】

Unknown   
Copyright © 2023 Housten, Rice, Chang, L’Hotta, Kim, Drake, Wright-Jones and Politi.